Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) EBIT Margin: 2014-2020

Historic EBIT Margin for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to 1,183.72%.

  • Larimar Therapeutics' EBIT Margin fell 147168.00% to 1,183.72% in Q1 2020 from the same period last year, while for Mar 2020 it was 2,293.55%, marking a year-over-year decrease of 73206.00%. This contributed to the annual value of 2,585.16% for FY2019, which is 63517.00% down from last year.
  • Larimar Therapeutics' EBIT Margin amounted to 1,183.72% in Q1 2020, which was down 41.15% from 2,011.33% recorded in Q4 2019.
  • In the past 5 years, Larimar Therapeutics' EBIT Margin registered a high of 166,975.00% during Q4 2017, and its lowest value of 1,183.72% during Q1 2020.
  • In the last 3 years, Larimar Therapeutics' EBIT Margin had a median value of 2,944.09% in 2018 and averaged 2,703.92%.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 15,617,603bps in 2017, then plummeted by 16,403,091bps in 2018.
  • Larimar Therapeutics' EBIT Margin (Quarterly) stood at 10,798.97% in 2016, then spiked by 15,617,603bps to 166,975.00% in 2017, then crashed by 16,403,091bps to 2,944.09% in 2018, then slumped by 93,276bps to 2,011.33% in 2019, then crashed by 147,168bps to 1,183.72% in 2020.
  • Its EBIT Margin stands at 1,183.72% for Q1 2020, versus 2,011.33% for Q4 2019 and 3,029.58% for Q3 2019.